Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The family Coronaviridae, within the order Nidovirales, contains two subfamilies, the Coronavirinae and the Torovirinae. Coronavirus (CoV) are a large group of viruses infecting mammals and birds and producing a wide variety of diseases. They have been divided into four genera, two of which contain viruses infecting humans (see later). All human coronaviruses (HCoVs) are primarily respiratory pathogens. The family Coronaviridae, within the order Nidovirales, contains two subfamilies, the Coronavirinae and the Torovirinae. Coronavirus (CoVs) are a large group of viruses infecting mammals and birds and producing a wide variety of diseases. They have been divided into four genera, two of which contain viruses infecting humans (see later). All human coronaviruses (HCoVs) are primarily respiratory pathogens.

**Definition**
- The coronaviruses (CoVs) commonly cause mild but occasionally more severe community-acquired acute respiratory infections in humans. CoVs also infect a wide variety of animals, and several CoVs [e.g., severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS)] have crossed the species barrier, producing outbreaks of severe respiratory disease. As of May 11, 2014, 537 cases of laboratory-confirmed MERS were reported to WHO with 145 deaths.

**Epidemiology**
- Community-acquired CoV infections cause about 15% of common colds. They are typically epidemic in the winter months. MERS has occurred in patients in the Arabian peninsula and those who recently traveled from this locale.

**Microbiology**
- CoVs are members of the Nidovirales order, single-stranded, positive-sense RNA viruses with a large genome. They mutate and also recombine frequently.

**Diagnosis**
- Laboratory diagnosis is best accomplished by finding viral RNA through polymerase chain reaction.

**Therapy**
- There are no accepted effective antiviral drugs for CoVs.

**Prevention**
- Prevention is through epidemiologic methods. The SARS epidemic was halted through careful case finding, quarantine, and use of barrier precautions.

**History**

**Respiratory Coronaviruses and Severe Acute Respiratory Syndrome**
In 1965, Tyrrell and Bynoe cultured a virus obtained from the respiratory tract of a boy with a common cold by passage in human embryonic tracheal organ cultures. The media from these cultures consistently produced colds in volunteers. The agent was ether sensitive but not related to any known human virus. Subsequently, electron microscopy of fluids from infected organ cultures revealed particles that resembled infectious bronchitis virus of chickens. At about the same time, Hamre and Procknow recovered a cytopathic agent in tissue culture from medical students with colds. The prototype virus was named 229E and was found on electron microscopy to have a similar or identical morphology (Fig. 157-1).

Using techniques similar to those used by Tyrrell and Bynoe, McIntosh and colleagues reported the recovery of several infectious bronchitis-like agents from the human respiratory tract, the prototype of which was named OC43 (OC for organ culture). At much the same time, mouse hepatitis virus and transmissible gastroenteritis virus of swine were shown to have the same morphology on electron microscopy. Shortly thereafter, the name coronavirus (the prefix corona denoting the crownlike appearance of the surface projections) was chosen to signify this new genus. The number of animal CoVs quickly grew, including viruses causing diseases in rats, mice, chickens, turkeys, various other bird species, cattle, several wild ruminants, beluga whales, dogs, cats, rabbits, and pigs, with manifestations in the respiratory and gastrointestinal tracts, central nervous system (CNS), liver, reproductive tract, and others. Through sequencing and antigenicity studies, the animal and human CoVs (HCoVs) initially were divided into three groups: group 1, which...
asthma; bat; bronchiolitis; coronavirus; MERS; Middle East respiratory syndrome; otitis; pneumonia; respiratory disease; ribonucleic acid; SARS; severe acute respiratory syndrome; zoonosis
Phylogenetic relationships among members of the subfamily Coronavirinae.

Virus                  Species              Genus
Miniopterus bat coronavirus 1A  AFCD62  Alphacoronavirus
Miniopterus bat coronavirus HKUB AFCD77
Porcine epidemic diarrhea virus GIV777  Betacoronavirus
Scotophilus bat coronavirus 512/2005
Human coronavirus 229E
Human coronavirus NL63 Amsterdam 1  Gammacoronavirus
Rhinolophus bat coronavirus HKU2-GD/430/2006
Transmissible gastroenteritis virus PUR46-MAD
Bovine coronavirus Mebus
Mouse hepatitis virus AS9
Human coronavirus HKU1-A  SARS-related coronavirus
Roussettus bat coronavirus HKUB-1 BF-0051
Tylohycteris bat coronavirus HKU4-1 B04f
Pipistrellus bat coronavirus HKU5 LMH03f
MERS coronavirus Hu/Jordan-N3/2012
Infectious bronchitis virus Beaudette
Beluga whale coronavirus SW1
Miniopterus coronavirus HKU13-3514
Munia coronavirus HKU11-934
Thrush coronavirus HKU12-600

FIGURE 157-1  Coronavirus, strain HCoV-229E, harvested from infected WI-38 cells (phosphotungstic acid stain). (From McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A. 1967;57:933-940.)

Chapter 157  Coronaviruses, Including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)
Connecticut. In all three cases, positive samples were from infants and children with respiratory disease. Notably, HCoV-NL63 and HCoV-229E were estimated to originate from a common precursor and diverge approximately 1000 years ago. HCoV-HKU1 was found in Hong Kong in an adult with respiratory disease. These two new HCoV strains subsequently have been found worldwide and appear to have pathogenicity similar to that of HCoV-229E and HCoV-OC43, with the possible exception that NL63 is more frequently found in children with croup.

The MERS-CoV was found when a man was admitted in June 2012 to a hospital in Jeddah, Saudi Arabia with overwhelming acute pneumonia with renal failure, and a sample of sputum grew a cytopathic virus that, on sequencing, proved to be a CoV, classified as a Betacoronavirus, and most closely related to two bat CoVs, HKU-4 and HKU-5. Over the next 23 months 536 additional cases (145 fatal) were found, all but a few of them sporadic or hospital-based and in individuals living or traveling in the Middle East.

In the remainder of this chapter, the group of respiratory HCoVs first discovered in the 1960s and containing HCoVs 229E, OC43, NL63, and HKU-1 are referred to as community-acquired HCoVs to distinguish them from the SARS-CoV and the MERS-CoV.

### Gastrointestinal Coronaviruses and Toroviruses

In view of the prominence of CoVs in animal enteric diseases, there have been extensive efforts to identify enteric HCoVs. There are numerous reports of CoV-like particles (CoVLPs) found by electron microscopy in human fecal matter, but these particles have been difficult to characterize further. More recent efforts to detect CoV RNA in feces using polymerase chain reaction (PCR) and primers for respiratory HCoVs have had limited success and have failed to associate CoVs with gastrointestinal disease.

Toroviruses were, like CoVs, first described in animals. They were first detected in the feces of cattle (Breda virus) and horses (Berne virus). Shortly thereafter, Beards and colleagues examined human fecal material and reported finding particles with a similar appearance that aggregated in the presence of antiserum to the bovine and equine viruses. The human toroviruses, like the bovine toroviruses, do not grow in tissue culture, and thus almost all existing information about them is based on electron micrographic data. Unlike animal toroviruses, PCR-amplified torovirus RNA sequences have not been found in human stool samples. A report of genome sequences amplified from particles purified from human stool was subsequently retracted and considered to reflect laboratory contamination from porcine strains.

At this time, there are no reports definitively showing the existence of human toroviruses.

### Description of the Pathogens

The CoV nucleic acid is RNA, approximately 30 kilobases in length, of positive sense, single stranded, polyadenylated, and infectious. The CoV nucleic acid is RNA, approximately 30 kilobases in length, of positive sense, single stranded, polyadenylated, and infectious. The RNA, the largest known viral RNA (Fig. 157-3), codes for (in order from the 5′ end) a large polyprotein that is cleaved by virus-encoded proteases.

---

**FIGURE 157-3** Genome organization of representative human coronaviruses. All coronavirus genomes have the same basic structure and mechanism of replication. The 5′ end of each genome encodes a leader sequence, which is attached to each virus-specific messenger RNA transcript by a novel mechanism of discontinuous replication. The first two thirds of each genome encode replicase-associated genes. Gene 1 is translated as two large polyproteins, with the first expressed from ORF1a and the second from ORF1b following a −1 frameshift event. These polyproteins are then cleaved into individual proteins by two virus-encoded proteases. The major structural genes, the hemagglutinin-esterase (HE), surface (S), envelope (E), transmembrane (M), and nucleocapsid (N) proteins, are indicated in green. The nonreplicase, accessory genes located at the 3′ ends of the genome are indicated with open boxes. The functions of these proteins are largely not known, and there is no sequence homology between accessory proteins of different coronaviruses. Some of these proteins are virion associated, but none are required for virus replication. The open reading frames (ORFs) encoding these proteins are numbered in order of appearance from the 5′ end of the genome, with the exception that ns12.9 of HCoV-OC43 is an internal protein expressed from an alternative reading frame located within the N gene. It is equivalent to SARS-CoV-specific protein 9b and the MERS-CoV-specific protein 8b. (Figure prepared by Rahul Vijay.)
proteases to form several nonstructural proteins, including an RNA-dependent RNA polymerase, methyltransferases, and a helicase, followed by either four or five structural proteins intermingled with a variable number of nonstructural and minor structural proteins. The first of the major structural proteins is a surface hemagglutinin-esterase protein, present on HCoVs OC43 and HKU1 and some animal betacoronaviruses, that may play some role in the attachment or release of the particle, or both, at the cell surface. This gene contains sequences similar to the hemagglutinin of influenza virus, likely evidence of an interfamily recombinational event that occurred many years ago. The next gene encodes the surface glycoprotein that forms the petal-shaped surface projections and is responsible for attachment and the stimulation of neutralizing antibody. This is followed by a small envelope protein, a membrane glycoprotein, and a nucleocapsid protein that is complexed with the RNA. There are several other open reading frames whose coding functions are not clear. The strategy of replication of CoVs is similar to that of other nidoviruses, in that all messenger RNAs form a nested set with common polyadenylated 3′ ends, with only the unique portion of the 5′ end being translated. As in other RNA viruses, mutations are common in nature, although the mutation rate is much lower, approximately 2 × 10-6 per site per replication cycle. Unlike other RNA viruses, CoVs encode a 3′-5′ exonuclease that has proofreading abilities, playing a critical role in maintaining replication fidelity in cell cultures and in animals. CoVs are also capable of genetic recombination if two viruses infect the same cell at the same time.

All CoVs develop exclusively in the cytoplasm of infected cells (Fig. 157-4). They bud into cytoplasmic vesicles from membranes of the pre-Golgi endoplasmic reticulum. These virus-filled vesicles are then extruded by the exocytic secretory pathway. The resultant virus particles have a diameter of 70 to 80 nm on thin-section electron microscopy and 60 to 220 nm on negative staining. They are pleomorphic, with widely spaced, petal-shaped projections 20 nm long (see Fig. 157-1).

The cellular receptor for 229E and most other alphacoronaviruses is aminopeptidase N (APN). Interestingly, NL63, the other known human alphacoronavirus, uses as its cellular receptor angiotensin-converting enzyme II (ACE2), the same receptor as is used by the SARS-CoV. Mouse hepatitis virus, a betacoronavirus related to strain OC43, uses as its receptor a member of the carinoembryonic antigen family. HCoV-OC43 and BCoV, which is closely related to HCoV-OC43, bind to 9-O-acetylated neuraminic acid as part of the entry process. The host cell receptor for MERS-CoV is dipeptidyl peptidase 4 (DPP-4), which, like ACE2 and APN, is an ectopeptidase that is abundantly expressed in the respiratory tract.

All the community-acquired respiratory HCoVs grow only with difficulty in tissue culture. Although this was true of 229E and NL63, both were discovered because they produced a detectable cytopathic effect, the first in human embryonic kidney and the second in LLC-MK2 cells. Both the SARS-CoV and the MERS-CoV were initially isolated and grown readily in Vero cells. HCoVs OC43 and HKU-1 have been grown in tissue culture after laboratory adaptation or in primary human airway epithelial cells. Detection of all these viruses in clinical specimens is most conveniently and sensitively achieved using PCR.

Likewise, the enteric CoVs have been difficult to cultivate in vitro. All but a few strains have been detected only by electron microscopy of human fecal material. Some strains have been characterized by immune electron microscopy and found to be related to HCoV-OC43. Two strains obtained from an outbreak of necrotizing enterocolitis in Texas and passed in intestinal organ cultures were reported to contain four or five proteins with apparent molecular weights similar to those of other CoVs but not related antigenically to known human strains or mouse hepatitis virus A59. The evidence favors the view that these isolates, as well as particles antigenically related to HCoV-OC43, are members of the family Coronaviridae, although their association with human disease is not yet proven. Surveys of children with diarrhea using PCR imply that diarrhea associated with the four well-described HCoV strains is unusual.

**Epidemiology**

**Community-Acquired Respiratory Coronaviruses**

Evidence of community-acquired respiratory CoV infections has been found wherever in the world it has been sought. In temperate climates, respiratory CoV infections occur more often in the winter and spring than in the summer and fall. The contribution of CoV infections to the total number of upper respiratory illnesses may be as high as 35% during times of peak viral activity. Overall, the proportion of adult colds produced by CoVs may be reasonably estimated at 15%.

Early studies of HCoV-OC43 and 229E in the United States demonstrated periodicity, with large epidemics occurring at 2- to 3-year intervals. Strain HCoV-229E tended to be epidemic throughout the United States, whereas strain HCoV-OC43 appeared in localized outbreaks. Similar studies of NL63 and HKU1 have not been done, but it seems from the available data that they also vary widely in incidence from year to year and place to place. Reinfection is common and may be due to the rapid diminution of antibody levels after infection. Infection occurs at all ages but is most common in children. The ratio of symptomatic to total infections varies between 50% and 90%, depending on the age of the population studied, the method of virus detection, and the definition of “infection.” Among adult volunteers 72% of those infected with HCoV-229E developed colds.

**Middle East Respiratory Syndrome Coronavirus**

The first report of a new CoV causing severe pneumonia appeared in ProMed Mail on September 20, 2012. A man from Jeddah, Saudi Arabia, had developed pneumonia in June and died of respiratory and renal failure, and a virus was grown from a sputum sample that was subsequently sequenced and found to be a betacoronavirus thought at the time to be most closely related to bat CoVs HKU4 and HKU5. Between then and May 2014, a total of 537 cases occurred, all infected by this virus, now termed the Middle East respiratory syndrome coronavirus (MERS-CoV). One hundred forty-five of the cases were fatal. More than 400 of these have been acquired and diagnosed in the Kingdom of Saudi Arabia, with most of the remainder in the United Arab Emirates, Qatar, Jordan, and Kuwait. Cases originating in the Arabian peninsula have also occurred in travelers to Egypt, Tunisia, Germany, Italy, Great Britain, Malaysia, the Philippines, and the United States, with a few secondary cases sometimes occurring in those locations through close family or hospital spread. In the United States, these include two unrelated MERS cases, and a third case related to one of these. While infections with severe respiratory involvement have
occurred at all ages, the elderly and those with underlying conditions (diabetes, renal disease, immunosuppression) have been most often severely or fatally affected. The WHO and the CDC have published a case definition, as well as surveillance instructions to aid in epidemiologic control of the MERS-CoV. The putative bat origin of this virus was strengthened by the finding that the virus grew readily in primary bat tissue culture. Nevertheless, and while bats sampled in the Middle East, Africa, and Europe were found to carry viruses closely related to the MERS-CoV, epidemiologic studies suggested there was likely to be at least one intermediate host. Serologic and virologic studies indicated that camels in the Middle East and Africa were frequently infected by viruses very similar to some of those found in human MERS cases. Acquisition of MERS from camels appears likely, although the proportion of camel-acquired cases (versus those acquired from person-to-person contact or through other animal intermediate) is not clear. Case clusters indicate that person-to-person hospital spread is more common than spread within families, and that casual-contact spread is unusual.

Severe Acute Respiratory Syndrome Coronavirus
The SARS epidemic began in Guangdong Province in the People’s Republic of China in mid-November 2002. It came to worldwide attention in March 2003 when cases of severe, acute pneumonia were reported to the World Health Organization from Hong Kong, Hanoi, and Singapore. Disease spread in hospitals to health care workers, visitors, and patients, among family members, and, on occasion, in hotels, apartment complexes, markets, and airplanes. Worldwide spread was rapid but focal (Fig. 157-3). The largest numbers of cases were reported from the People’s Republic of China, Hong Kong, Taiwan, Singapore, and Toronto, Canada. The overall case-fatality rates in these locations ranged from 7% to 17%, but persons with underlying medical conditions and those older than 65 years of age had mortality rates as high as 50%. There was no mortality in children or young adults younger than the age of 24 years.

In response to the global spread and associated severe disease, the World Health Organization coordinated a rapid and effective control program that included isolation of cases, careful attention to contact, droplet and airborne infection control procedures, quarantine of exposed persons in some settings, and efforts to control spread between countries through travel advisories and travel alerts. Presumably as a result of these efforts, global transmission ceased by July 2003.

A few subsequent cases of SARS were detected, but all were either a result of laboratory spread or individual cases related to presumed contact with civet cats or other intermediate hosts. The last known case occurred in mid-2004.

Spread of SARS to humans is thought to have occurred primarily through droplet or contact transmission, with a possible role for fomites. In most instances, an individual case transmitted to very few others, although several well-documented instances of small-particle airborne transmission occurred, resulting in super-spreading events. Spread in hospital settings appeared to be surprisingly efficient, but it could be effectively suppressed with the enforcement of droplet and contact precautions. Containment measures were efficacious, in part, because patients were most contagious only after lower respiratory disease developed. The chain of spread was finally broken in the People’s Republic of China, the last country to experience endemic spread, in June 2003.

It now seems almost certain that the human epidemic began with the spread of a closely related bat virus first to palm civets or other animals sold in live wild game markets and then to humans in Guangdong Province in the People’s Republic of China, and that the virus adapted itself through mutation and possibly recombination, until it transmitted readily among humans. The virus that spread worldwide came largely from a single infected individual who traveled from...
Guangdong Province to Hong Kong and infected a large number of individuals before himself succumbing to the disease. In contrast, the virus that was epidemic in the People’s Republic of China was more variable.

**Gastrointestinal Coronaviruses**

Although an etiologic role is not proven, enteric CoVs (or CoVLPs) have been most frequently associated with gastrointestinal disease in neonates and infants younger than 12 months. Particles have been found in the stools of adults with the acquired immunodeficiency syndrome. Asymptomatic shedding is common, particularly in tropical climates and in populations living in poor hygienic conditions. The viruses can be detected for prolonged periods and without any apparent seasonal pattern.

**PATHOGENESIS**

**Community-Acquired Respiratory Coronaviruses**

Community-acquired respiratory CoVs (HCoV-229E, OC43, NL63, HKU-7) generally replicate in ciliated and nonciliated (HCoV-229E) epithelial cells of the nasopharynx, probably producing both direct cell degeneration and an outpouring of chemokines and interleukins, with a resultant common-cold symptom complex similar to that produced by rhinovirus infection. The incubation period is, on average, 2 days, and the peak of respiratory symptoms, as well as viral shedding, is reached at approximately 3 or 4 days after inoculation.

The pattern of virus replication of CoVs must be at least in part determined by virus-receptor interaction. The two best-defined receptors for the respiratory CoVs are aminopeptidase N for strain HCoV-229E and angiotensin-converting enzyme II for NL63.

**SARS-CoV and MERS-CoV**

The pathogenicity of SARS is more complex and involves systemic spread. The route of infection of the SARS-CoV is probably through the respiratory tract. After an incubation period that is usually 4 to 7 days, but can be as long as 10 to 14 days, the disease begins, starting usually with fever and other systemic (influenza-like) symptoms, with cough and dyspnea developing a few days to a week later. Although the lung is the focus of the disease process, there are often signs of involvement in other organ systems, including diarrhea, leukopenia, thrombocytopenia, and, most notably, pan-lymphopenia. Virus has been detected in respiratory secretions, blood, stool, and urine specimens and tissue from the lung and kidney. On the basis of PCR testing, virus titer is highest during the second week of illness and can often be detected into the third week of illness and sometimes for as long as several months. Pulmonary symptoms may worsen late in the course of the illness, with the development of adult respiratory distress syndrome. There may also be late evidence of liver and kidney involvement.

The pulmonary pathology of infection by the SARS-CoV has been described extensively, but little has been published about the pathology in other organ systems. The extrapulmonary pathologic changes found most consistently at autopsy are extensive necrosis of the white pulp of the spleen and a generalized small vessel arteritis. In the lung, there is hyaline membrane formation, interstitial infiltration with lymphocytes and mononuclear cells, and desquamation of pneumocytes in the alveolar spaces. Giant cells are a constant finding and usually have macrophage markers. In bronchoalveolar lavage, biopsys, and autopsy specimens viral particles have been noted in type I and II pneumocytes.

At this point, little is known about the pathogenesis of MERS-CoV because the infection was only recently described and no pathological specimens are yet available. It is anticipated that the pathologic changes in the lungs of patients with severe disease will be similar to those observed in patients with SARS or other patients with acute respiratory distress syndrome (ARDS).

**CLINICAL MANIFESTATIONS**

**Community-Acquired Respiratory Coronaviruses**

Almost all the antigenically distinct respiratory CoV strains that were isolated in the 1960s have been administered to volunteers, and all these produce illness with similar characteristics. A summary of these characteristics is given in Table 157-1, in which a comparison is made with colds produced by rhinoviruses in similarly inoculated volunteers. The incubation period of CoV colds was longer and their duration somewhat shorter, but the symptoms were similar. Asymptomatic infection was sometimes seen and, indeed, has been a feature

| FEATURE | CORONAVIRUSES | RHINOVIRUSES |
|---------|---------------|--------------|
|         | 229E | B814 | Type 2 (HGP or PK) | DC |
| No. of volunteers inoculated | 26 | 75 | 213 | 251 |
| No. (%) getting colds | 13 (50) | 34 (45) | 78 (37) | 77 (31) |
| Incubation period (days) | | | | |
| Mean | 3.3 | 3.2 | 2.1 | 2.1 |
| Range | 2-4 | 2-5 | 1-5 | 1-4 |
| Duration (days) | | | | |
| Mean | 7 | 6 | 9 | 10 |
| Range | 3-18 | 2-17 | 3-19 | 2-26 |
| Maximum no. of handkerchiefs used daily | | | | |
| Mean | 23 | 21 | 14 | 18 |
| Range | 8-105 | 8-120 | 3-38 | 33-60 |
| Malaise (%) | 46 | 47 | 28 | 25 |
| Headache (%) | 85 | 53 | 56 | 56 |
| Chill (%) | 31 | 18 | 28 | 15 |
| Pyrexia (%) | 23 | 21 | 14 | 18 |
| Mucopurulent nasal discharge (%) | 0 | 62 | 83 | 80 |
| Sore throat (%) | 54 | 79 | 87 | 73 |
| Cough (%) | 31 | 44 | 68 | 56 |
| No. (%) of volunteers with colds of indicated severity | | | | |
| Mild | 10 (77) | 24 (71) | 63 (80) | 36 (47) |
| Moderate | 2 (15) | 7 (20) | 12 (15) | 28 (36) |
| Severe | 1 (8) | 3 (9) | 4 (5) | 13 (17) |

From Bradburne AF, Bynoe ML, Tyrrell DAJ. Effects of a “new” human respiratory virus in volunteers. Br Med J. 1967;3:767-769.
of both serologic surveys and PCR-based studies of natural infection of infants, children, and adults.\textsuperscript{92,93}

More serious respiratory tract illness is probably also caused by all four strains of community-acquired HCoV. The evidence for this is not conclusive, but it seems likely that all strains can produce pneumonia and bronchiolitis in infants.\textsuperscript{43,27,74,93} otitis and exacerbations of asthma in children and young adults,\textsuperscript{96-99} pneumonia in healthy adults,\textsuperscript{99} exacerbations of asthma and chronic bronchitis in adults,\textsuperscript{100,101} both serious bronchitis and pneumonia in the elderly,\textsuperscript{102,103} and pneumonia in the immunocompromised host.\textsuperscript{94,95} HCoVs are found in asymptomatic individuals of all ages, and, when accompanied by illness, are also sometimes accompanied by infections with other potential respiratory pathogens. These characteristics (infection without disease, coinfection during disease) are features of many respiratory pathogens, including particularly rhinoviruses, adenoviruses, human metapneumovirus, human bocavirus, and parainfluenza viruses, but also (although less frequently) respiratory syncytial virus and influenza virus. Because infections with respiratory HCoVs are so common, however, it is possible that they are responsible for a significant portion of these serious lower respiratory tract diseases, even though the basic pathogenicity of HCoVs (judging from volunteer studies) is similar to that of rhinoviruses, and clearly less than that of respiratory syncytial virus, influenza viruses, and certain adenovirus types. There is some evidence that HCoV-OC43 is more pathogenic in the elderly than HCoV-229E,\textsuperscript{106} and also some evidence that infection with NL63 in children is different from the other respiratory HCoVs in that several series have found an excess of children with croup.\textsuperscript{96,97}

**Middle East Respiratory Syndrome Coronavirus**

Information about the clinical presentation of patients infected with the MERS-CoV is limited. It is clear that there is a spectrum of illness with some infections consisting of mild upper respiratory symptoms only, and others characterized by cough and fever with progression to respiratory failure over about a week.\textsuperscript{6,7,62,107} Renal failure, as well as pericarditis and adult respiratory distress syndrome has been part of the reported clinical picture. The MERS-CoV host cell receptor, DPP-4, is expressed at high levels in the kidney,\textsuperscript{108} raising the possibility that direct infection of this organ contributes to renal disease.

A case definition that will lead to further epidemiologic studies has been published by the World Health Organization.\textsuperscript{109}

**Severe Acute Respiratory Syndrome Coronavirus**

The first symptom in most cases of SARS was fever, usually accompanied by headache, malaise, or myalgia. This was followed, usually in a few days, but as long as a week later, by a nonproductive cough and, in more severe cases, dyspnea. Approximately 25% of patients had diarrhea. Interestingly, upper respiratory symptoms such as rhinorrhea and sore throat usually did not occur.\textsuperscript{52,64,110-113} The chest radiograph was frequently abnormal, showing scattered air-space opacification, usually in the periphery and lower zones of the lung.\textsuperscript{14} Spiral computed tomography demonstrated both ground-glass opacification and consolidation, often in a subpleural distribution.\textsuperscript{115-117} Lymphopenia was common,\textsuperscript{84,96,110} with normal or somewhat depressed neutrophils. Paradoxically, neutrophilia was associated with poor outcomes.\textsuperscript{87} The decrease in lymphocytes in the blood was most marked for CD4 cells but was seen in all T-cell phenotypes, including CD3 and CD8, as well as natural killer cells. Creatine kinase was often abnormal, as were lactic dehydrogenase and aspartate aminotransferase. Levels of proinflammatory cytokines were elevated at early times during infection in patients with severe clinical disease\textsuperscript{118} and decreased in those patients who resolved the infection.\textsuperscript{119}

Approximately 25% of patients developed severe pulmonary disease that progressed to adult respiratory distress syndrome. Adult respiratory distress syndrome with SARS-CoV infection was most likely to develop in patients older than 50 years or with underlying disease such as diabetes, cardiac disease, and chronic hepatitis.\textsuperscript{115,117,120} The overall mortality rate was between 9% and 12%, with the highest rates in the elderly and adults with underlying liver disease. In some patients, clinical deterioration occurred during the second week of illness, as virus levels decreased, suggesting that disease was partly immune mediated.\textsuperscript{4} Clinical improvement was associated with the onset of a virus-specific antibody response.\textsuperscript{119}

Pediatric disease was, interestingly, significantly less severe than adult disease, although the features were similar.\textsuperscript{121} Disease during pregnancy was severe, with high mortality in both the mother and fetus.\textsuperscript{122} Congenital transmission was not described.

**Gastrointestinal Coronavirus**

The nature of the illness associated with enteric CoV infection is much less clear. One study found a significant association of gastroenteritis in infants 2 to 12 months of age with the presence of CoVLPs in the stool.\textsuperscript{123} Another study, confined to infants in a neonatal intensive care unit, found highly significant associations between the presence of CoVLPs in the stool and the presence of water-loss stools, bloody stools, abdominal distention, and bilious gastric aspirates.\textsuperscript{3} A further study of symptomatic infants shedding CoVLPs pointed to possible differences between CoVLP-associated diarrhea and rotavirus diarrhea: Although fever and vomiting were of similar incidence, stools were more often occult blood positive (18% in CoVLP-associated vs. 0% in rotavirus-associated disease), less often watery (66% vs. 92%), and more often mucoid (32% vs. 8%).\textsuperscript{77} Finally, CoVs have been associated with at least three outbreaks of necrotizing enterocolitis in newborns,\textsuperscript{72,33,94} and the best characterized strains\textsuperscript{96} were isolated in infants with this illness.

Surveys seeking HCoV RNA by PCR using primers that would detect the known community-acquired respiratory HCoVs in stool have been quite disappointing. In one study of 878 fecal samples from children with gastrointestinal complaints tested over 2 years, all four HCoV species were found, but in all but 4 of 22 HCoV-positive cases, either rotavirus or norovirus was also present.\textsuperscript{28} In addition, about half of the children in this survey had respiratory and gastrointestinal symptoms. In the same study, 112 asymptomatic children were sampled and 2 were positive. Another study sampled 151 symptomatic children, and 2 were found to have HKU1 RNA.\textsuperscript{29} Molecular studies using primers that would broadly detect new CoVs should be considered to resolve questions about the role of CoVs in human gastrointestinal disease.\textsuperscript{124}

**Neurologic Syndromes**

Like many other viruses, CoVs have been sought as possible etiologic agents in multiple sclerosis. The search has been stimulated by the capacity of JHM, a well-studied strain of mouse hepatitis virus, to produce in mice and rats an immune-mediated chronic demyelinating encephalitis histologically similar to multiple sclerosis.\textsuperscript{125} HCoV-OC43\textsuperscript{125,126} and HCoV-229E\textsuperscript{127} have been detected in brain tissue from multiple sclerosis patients using virus isolation,\textsuperscript{128} in situ hybridization,\textsuperscript{129} immunohistology,\textsuperscript{130} and PCR.\textsuperscript{131} Moreover, T-cell lines established from patients with multiple sclerosis by stimulation with myelin basic protein or HCoV-229E were found to be cross-reactive with the opposite antigen, suggesting that molecular mimicry might be a possible pathogenic mechanism for the disease association.\textsuperscript{132} An adolescent boy with acute demyelinating encephalitis was found to have HCoV-OC43 RNA in both the respiratory tract and the cerebrospinal fluid.\textsuperscript{129} Despite these intriguing reports, compelling evidence is lacking to establish an etiologic or pathogenetic association of CoVs with CNS disease in humans.

**Laboratory Diagnosis**

**Respiratory Coronavirus**

Although some human respiratory CoVs grow in tissue culture directly from clinical samples and although antigen detection systems have been developed for both HCoV-OC43 and HCoV-229E,\textsuperscript{38,133} laboratory diagnosis of CoV respiratory infections is best accomplished by molecular methods. Reverse-transcriptase PCR (RT-PCR) systems have been developed using many different primers and detectors. From a clinical point of view, a single generic test for respiratory CoVs would be desirable, and such tests have been developed. However, when tested side by side with specific systems, the generic systems have a somewhat lower sensitivity.\textsuperscript{3} Systems that combine primers and probes specific for several CoVs have also had considerable success.\textsuperscript{134}
Frequently during the second week of illness. 18,84,85

The complete reference list is available online at Expert Consult.

Characteristic particles in negatively stained specimens. Such testing is entirely on electron microscopy of stool specimens and detection of Laboratory diagnosis of the gastrointestinal CoVs depends now 4 weeks.84

Nosorbent assay. Immunoglobulin M antibody can be detected in virus and indirect immunofluorescence or enzyme-linked immuno- 

tification by PCR. 133 Current recommendations from WHO are that authority, and clinical, epidemiologic, and microbiologic investigations should be carried out.85

Severe Acute Respiratory Syndrome Coronavirus

Although SARS-CoV was grown from respiratory tract specimens in Vero E6 and fetal rhesus monkey kidney cells, the more sensitive and rapid RT-PCR assays were most widely used to detect infection. Virus was detected by RT-PCR in upper and lower respiratory tract biopsies, stool, and urine specimens. Early in the illness, specimens were found positive only in approximately one third of patients.84 Use of samples from multiple sources increased the yield. Virus was detected most frequently during the second week of illness.18,84,85

Antibody tests have been developed using tissue culture–grown virus and indirect immunofluorescence or enzyme-linked immuno-

Gastrointestinal Coronavirus

Laboratory diagnosis of the gastrointestinal CoVs depends now entirely on electron microscopy of stool specimens and detection of characteristic particles in negatively stained specimens. Such testing is best performed in laboratories with extensive previous experience.

Therapy

Given the severity of SARS, clinicians throughout the world empirically treated most patients with corticosteroids and intravenous or oral ribavirin.134 It is now known that ribavirin has little activity against SARS-CoV in vitro, and there is no evidence that either intervention improved outcomes.135,136 Lopinavir/ritonavir and intravenous immunoglobulin were also used in some patients, again without conclusive evidence that they were helpful or harmful. There is anecdotal and at least partially controlled evidence of the benefit of either interferon-α or interferon-β treatment. Further, treatment of SARS-CoV-infected cynomolgus monkeys with pegylated interferon-α resulted in improved outcomes,137 lending credence to the use of this therapy if SARS recurred.

Treatment of MERS-CoV infection depends entirely on supportive measures. No antiviral drugs are recommended, although several studies have indicated that MERS-CoV is more sensitive to interferon-α or interferon-β than SARS-CoV.138,139 Standard droplet precautions should be used, with aerosol precautions during certain high-risk procedures.109

Prevention

Rigorous application of hospital infection control procedures, particularly those directed at contact and droplet spread, was shown to have a major beneficial effect on the spread of the SARS-CoV.108 The containment of the global SARS outbreak is a testament to the power of the cooperation and collaboration engendered by the World Health Organization to address a major public health threat. Similar precautions are recommended for patients with suspected or confirmed MERS-CoV infections.109

Vaccines for animal CoVs have been developed and widely used with variable efficacy. In one instance, a vaccine for feline infectious peritonitis appeared to lead to enhanced disease with subsequent natural infection. If SARS does return or MERS reaches epidemic proportions, an effective vaccine would be extremely helpful in control efforts, and a variety of vaccination strategies, including inactivated, subunit, and live-attenuated vaccines, are being pursued.135 In addition, hospitals have been advised on improvement of infection control procedures so that in future epidemics of respiratory viruses, they will no be a major source of spread of infection, as occurred in the 2002 epidemic of SARS.

Key references

The complete reference list is available online at Expert Consult.

1. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005;102:14040-14045.
2. Guan Y, Zhong BS, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276-278.
3. Lai MM, Perlman S, Anderson LJ. Coronavirusidae. In: Knipe DM, Howley PM, eds. Fields Virology. 5th ed. Lippincott Williams & Wilkins, 2007.
4. Perlman S, Neal J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7: 439-450.
5. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-1820.
6. Assiri A, McGregor A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407-416.
7. Tyrrell DAJ, Byrnes ML. Cultivation of a novel type of common-cold virus in organ cultures. Br Med J. 1965;1: 1467-1470.
8. Almeida JD, Tyrrell DAJ. The morphology of three previ- ously uncharacterized human respiratory viruses that grow in group culture. J Gen Virol. 1967;1:175-178.
9. Hamre D, Procknow J. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med. 1966;121: 190-193.
10. McIntosh K, Dees JH, Becker WB, et al. Recovery in tra- cheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A. 1967;57: 933-940.
11. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syn- drome. Nature Med. 2004;10:588-597.
12. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361:1319-1325.
13. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coro- navirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953-1966.
analysis and virus cultured from dromedary camels in Saudi Arabia. MBio. 2014;5:e01146-14. 68. Seto WH, Tsang D, Yung RW, et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet. 2003;361:1519-1520. 69. Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133:74-87. 70. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science. 2004;303:1666-1669. 71. Petris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-1772. 72. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2003;202:415-424.
van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of coronavirus as a possible cause of severe acute respiratory syndrome. J Clin Virol 2010;48:201-492.

Pyrc K, Dijkstra R, Deng L, et al. Mosaic structure of human coronavirus NL63, one thousand years of evolution. Arch Virol 2004;149:966-97.

van der Hoek L, Sure K, Thorst G, et al. Group is associated with the novel coronavirus NL63. PLoS Med 2005;2:486-94.

Choi EH, Lee HJ, Kim SJ, et al. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children. 2000-2005. Clin Infect Dis 2006;43:585-92.

Risku M, Lippalainen S, Rasani S, Vesikari T. Detection of human coronaviruses in children with acute gastroenteritis. J Clin Virol 2010;48:27-30.

References

1. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005;102:14040-14045.

2. Vyas KR, Gahne T, Smith GL, Zhang JX, et al. Evolutionary insights into the ecology of coronaviruses. J Virol 2007;81:4012-4020.

3. Guan Y, Zhang BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.

4. Lai MM, Perlman S, Anderson LJ. Coronaviridae. In Knipe DM, Howley PM, eds. Fields Virology, 5th ed. Lippincott Williams & Wilkins, 2007.

5. Perlman S, Neijland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009;7:439-450.

6. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a new coronavirus from a man with pneumonia in Saudi Arabia. N Eng J Med 2012;367:1814-1820.

7. World Health Organization. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Summary and Literature Review to 30 May 2014. Available at: http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua=1. Accessed May 13, 2014.

8. Assiri A, McGregor A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013;369:867-876.

9. Tyrrell DAJ, Bynoe ML. Cultivation of a novel type of enveloped virus in culture. Br Med J 1965;1:1467-1470.

10. Almeida JD, Tyrrell DAJ. The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J Gen Virol 1967;1:175-178.

11. Hamer D, Procknow J. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966;120:193-199.

12. McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A 1967;57:933-940.

13. McIntosh K, Becker WB, Chanock RM. Growth in suckling mouse brain of “IBV-like” viruses from patients with upper respiratory tract disease. Proc Natl Acad Sci U S A 1967;55:2268-2273.

14. Witte KE, Tajima M, Easterday BC. Morphologic characteristics and nucleic acid type of transmissible gastroenteritis virus of pigs. Arch Gesamte Viruhrsch 1968;25:33-70.

15. Tyrrell DAJ, Almeida JD, Chanock RM, et al. Coronavirus. Interlaboratories. 1975;5:56-82.

16. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature Med 2004;10:588-597.

17. Peiris JS, Lau ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1139-1142.

18. Kussan GM, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-1966.

19. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus associated with severe acute respiratory syndrome cases. Nature 2003;403:1334-1339.

20. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Lancet 2004;363:2059-2070.

21. Payne CM, Ray CG, Borduin V, et al. An eight-year study of the epidemiology of coronavirus-like particles in adults in Melbourne, Australia. Emerg Infect Dis 2013;19:456-459.

22. Brier T, Mubiru N, Jain K, et al. Middle East respiratory syndrome coronavirus of bats: evidence for re-emerging retroviruses with potential pathogenicity. J Acquir Immune Defic Syndr 2010;56:1218-1223.

23. Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS). Available at: http://www.cdc.gov/sars/coronavirus/sars/def.html. Accessed May 13, 2014.

24. World Health Organization. Interim Surveillance Recommendations for Human Infection with Middle East Respiratory Syndrome Coronavirus. June 27, 2013. Available at: http://www.who.int/csr/disease/coronavirus_infections/InterimRevisedSurveillanceRecommendations_nCoV_infection_27Jun13.pdf?ua=1. Accessed May 13, 2014.

25. Centers for Disease Control and Prevention. Middle East Respiratory Syndrome (MERS). Case Definitions. Available at: http://www.cdc.gov/coronavirus/mers/case-def.html. Accessed May 13, 2014.

26. Annan AM, Coen EM, Cormann VM, et al. Human beta-coronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 2013;19:456-459.

27. Brier T, Mubiru N, Jain K, et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus culture from dromedary camels in Saudi Arabia. MBio 2013;4:1-14.

28. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-720.

29. Severe acute respiratory syndrome—Singapore, 2003. MMWR Morb Mortal Wkly Rep 2003;52:405-411.

30. SETI, TS, DANG S, YUNG RW, et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003;361:1299-1302.

31. HUNG IF, Cheng VC, WU AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 2004;10:222-226.

32. SHI Z, HU Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 2008;133:74-87.

33. SCHMIDT W, Schneider W, Reise W, et al. Stool viruses, coinfections, and diarrhea in HIV-infected patients. Berlin Diarrhea/Wasting Study Syndrome Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:33-38.

34. MARSHALL JA, BURCH WJ, LAMAY J, et al. Coronavirus-like particles and other agents in the faeces of children in Elate, Vanuatu. J Trop Med Hyg 1982;85:213-215.

35. MARSHALL JA, THOMPSON WL, GUST ID. Coronavirus-like particles in adults in Melbourne, Australia. J Med Virol 1989;29:238-243.

36. MORTENSEN ML, PAYNE CM, et al. Coronaviruses in human gastrointestinal disease: epidemiologic, clinical, and laboratory observations. Am J Dis Child 1985;139:928-934.

37. PAYNE CM, RAY CG, BORDUIN V, et al. An eight-year study of the viral agents of acute gastroenteritis in humans: ultrastructural observations and seasonal distribution with a major emphasis on coronaviruses. J Gen Virol 1988;69:53-54.

38. Dijkstra R, Rieffin MF, Koekkoom SK, et al. Isolation and characterization of human enteric coronavirus. Science 1985;229:78-81.

39. MONTO AS. Medical reviews: coronaviruses. Yale J Biol Med 1974;47:234-251.

40. CALLAW KA, Parry HE, Sergeant M, et al. The time course of a group A rotavirus infection: evidence from a longitudinal cohort study. Diagn Microbiol Infect Dis 1985;5:235-240.

41. GRAJ MJ, SCHOUTEN EG, HEIJNE ML, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol 2003;56:1218-1223.

42. PRILL MM, Iwane MK, Edwards KM, et al. Human coronavirus infections in young children: acute respiratory illness and asymptomatic infections. Pediatr Infect Dis J 2011;30:235-240.

43. BRADBURY RF, BYRNE ML, TYRRELL DA. Effects of a “new” human respiratory virus in volunteers. Br Med J 1967;3:767-769.

44. SETI, TS, DANG S, YUNG RW, et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003;361:1299-1302.
